- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gynecologic Cancers | Clinical
Intermittent Relacorilant With Nab-Paclitaxel Leads to OS Benefit in Pretreated Ovarian Cancer Population
July 13, 2022
Treatment with relacorilant showed improvement in overall survival in patients platinum-resistant or platinum-refractory ovarian cancer when combined with nab-paclitaxel.
Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial Cancer
June 08, 2022
Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.
Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical Cancer
June 06, 2022
Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.
Lenvatinib/Pembrolizumab Combo Improves Efficacy of Next Line of Therapy in Advanced Endometrial Cancer
June 05, 2022
An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.
Adjuvant Immunotherapy Combinations Are Explored in Endometrial Cancer
May 20, 2022
The benefit of pembrolizumab compared with placebo in combination with adjuvant chemotherapy with or without radiation therapy in patients with newly diagnosed high-risk endometrial cancer after surgery with curative intent is under evaluation in the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.
Promising Response Shown With VB10.16 Plus Atezolizumab in HPV16+ Cervical Cancer
May 10, 2022
The phase 2 VB C-02 trial examining VB10.16 in combination with atezolizumab demonstrated positive results in patients with HPV16-positive advanced cervical cancer.
FDA Grants Fast Tracks SQZ-PBMC-HPV for HPV16+ Advanced/Metastatic Solid Tumors
April 28, 2022
The FDA has granted fast track designation to SQZ-PBMC-HPV for the treatment of patient with HPV16-positive advanced or metastatic solids tumors, according to an announcement by SQZ Biotechnologies.
DUO-E Trial Focuses on Treating High-Risk Endometrial Cancer
April 21, 2022
Shannon N. Westin, MD, MPH, FACOG, discusses the endometrial cancer patient population enrolled in the phase 3 DUO-E trial.
Early Signs of Clinical Promise Noted for Neoadjuvant Chemoimmunotherapy in Advanced Ovarian Cancer
April 13, 2022
Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.
HPV Infection Determines Prognosis in Patients with Invasive Cervical Cancer
April 13, 2022
High risk human papillomavirus infection appears to be a strong determinant of cervical cancer prognosis over 15 years after diagnosis.